Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 7/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 5/20 | 0.32 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1406875 | 0.78 | L3MBTL1 (0.59) | L3MBTL1SMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL12434763 | 0.76 | L3MBTL1 (0.43) | L3MBTL1SMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL2317402 | 0.76 | L3MBTL1 (0.43) | L3MBTL1SMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL19730080 | 0.75 | GABRA1 (0.33) | SMN1; SMN2GABRA1MEN1KMT2A | |
| SCHEMBL27478868 | 0.73 | GABRA1 (0.33) | GABRA1MAPT | |
| SCHEMBL1407142 | 0.71 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1MAPTKDM4EALOX15 | |
| SCHEMBL17853199 | 0.69 | GABRA1 (0.37) | GABRA1ALDH1A1KDM4EGAAKMT2A | |
| SCHEMBL2320009 | 0.66 | HSD11B1 (0.56) | SMN1; SMN2ALDH1A1KDM4EPOLB | |
| SCHEMBL16245836 | 0.66 | SLC9A1 (0.65) | L3MBTL1SMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL14922174 | 0.65 | MAPT (0.36) | L3MBTL1GABRA1ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
| US-9856260-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2016-09-15 | — | — | US | disclosed |
| US-9375474-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2016-06-28 | — | — | US | disclosed |
| US-9375474-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2016-06-28 | — | — | US | disclosed |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | Alliance Discovery, Inc. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | Alliance Discovery, Inc. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8435993-B2 | Methods of inhibiting metastasis from cancer | PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435993-B2 | Methods of inhibiting metastasis from cancer | PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| WO-2012078633-A2 | METHODS OF INHIBITING METASTASIS FROM CANCER | PHILADELPHIA HEALTH AND EDUCATION CORPORATION, D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICENE (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | Alliance Discovery, Inc. | 2012-06-07 | — | — | US | disclosed |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | Alliance Discovery, Inc. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | L3MBTL1 4128/4885SMN1; SMN2 3695/4885GABRA1 3338/4885 |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | CX3CR1, CCL2, CCR5 | L3MBTL1 4128/4885SMN1; SMN2 3695/4885GABRA1 3338/4885 |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | CX3CR1, CXCR3, CCR5 | L3MBTL1 3623/4885SMN1; SMN2 3265/4885GABRA1 3222/4885 |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | L3MBTL1 4128/4885SMN1; SMN2 3695/4885GABRA1 3338/4885 |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | L3MBTL1 4128/4885SMN1; SMN2 3695/4885GABRA1 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.